Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C, Maheu-Giroux M, Marathe G, Saeed S, Martel-Laferrière V, Cooper CL, Walmsley S, Cox J, Wong A, Klein MB; Canadian Coinfection Cohort investigators. Lanièce Delaunay C, et al. Among authors: cooper cl. Int J Drug Policy. 2022 May;103:103627. doi: 10.1016/j.drugpo.2022.103627. Epub 2022 Feb 24. Int J Drug Policy. 2022. PMID: 35218989 Free article.
CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy.
Klein MB, Cooper C, Brouillette MJ, Sheehan NL, Benkelfat C, Annable L, Weston F, Kraus D, Singer J; CTN194 Investigators. Klein MB, et al. Contemp Clin Trials. 2008 Jul;29(4):617-30. doi: 10.1016/j.cct.2008.01.001. Epub 2008 Jan 12. Contemp Clin Trials. 2008. PMID: 18262853 Clinical Trial.
Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries.
Raboud JM, Loutfy MR, Su D, Bayoumi AM, Klein MB, Cooper C, Machouf N, Rourke S, Walmsley S, Rachlis A, Harrigan PR, Smieja M, Tsoukas C, Montaner JS, Hogg RS; CANOC Collaboration. Raboud JM, et al. BMC Infect Dis. 2010 Feb 25;10:40. doi: 10.1186/1471-2334-10-40. BMC Infect Dis. 2010. PMID: 20184766 Free PMC article.
Once daily dosing improves adherence to antiretroviral therapy.
Raboud J, Li M, Walmsley S, Cooper C, Blitz S, Bayoumi AM, Rourke S, Rueda S, Rachlis A, Mittmann N, Smieja M, Collins E, Loutfy MR. Raboud J, et al. AIDS Behav. 2011 Oct;15(7):1397-409. doi: 10.1007/s10461-010-9818-5. AIDS Behav. 2011. PMID: 20878227
Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.
Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, Loutfy MR, Raboud J, Rachlis A, Ding E, Lima VD, Montaner JS, Rourke SB, Smieja M, Tsoukas C, Hogg RS; CANOC Collaboration. Cescon AM, et al. HIV Med. 2011 Jul;12(6):352-60. doi: 10.1111/j.1468-1293.2010.00890.x. Epub 2010 Nov 8. HIV Med. 2011. PMID: 21059167 Free article.
A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression.
Loutfy MR, Genebat M, Moore D, Raboud J, Chan K, Antoniou T, Milan D, Shen A, Klein MB, Cooper C, Machouf N, Rourke SB, Rachlis A, Tsoukas C, Montaner JS, Walmsley SL, Smieja M, Bayoumi A, Mills E, Hogg RS; CANOC Collaboration. Loutfy MR, et al. J Acquir Immune Defic Syndr. 2010 Dec;55(4):451-9. doi: 10.1097/qai.0b013e3181ec28ff. J Acquir Immune Defic Syndr. 2010. PMID: 21105259
437 results